Exciting, but Costly
The cytokine- and antibody-targeted drugs for various asthma phenotypes are nothing short of revolutionary. Entire journal editions[1] have been devoted to these biologic therapies. The excitement surrounding these medications is tempered only by their cost—and that cost is not so transparent. Published prices are not necessarily those paid by insurers, and the cost of biologic drugs can also vary greatly depending on the agent and the patient's weight.[2] Drug costs presented herein are estimates only and will change over time owing to many factors, including insurance contracts.
Anti-Immunoglobulin E Monoclonal Antibody
The cost of Xolair per patient is variable and depends on the patient's weight and immunoglobulin E (IgE) level. This can vary from a small patient with a low IgE level requiring a single monthly 150-mg vial of Xolair, with an annual average wholesale price (AWP) of $12,586,[3] to a patient who is heavier and/or with a higher IgE level receiving 375 mg every 2 weeks, equating to a cost (on the high end) of approximately $81,809 annually.
Anti-Interleukin 5 Monoclonal Antibody
Mepolizumab (Nucala®) is a 100-mg monthly subcutaneous injection for all patients. On the basis of AWP, the annual price is $37,080.[4]
Reslizumab(Cinqair®) is a monthly intravenous infusion and weight-based at 3 mg/kg.
